CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.
Aged
Aged, 80 and over
CD13 Antigens
/ biosynthesis
Cell Differentiation
Cohort Studies
Female
Flow Cytometry
Gene Expression Regulation, Neoplastic
Humans
Lymphoma, B-Cell, Marginal Zone
/ diagnosis
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Plasma Cells
/ metabolism
RNA, Messenger
/ biosynthesis
RNA, Neoplasm
/ biosynthesis
Waldenstrom Macroglobulinemia
/ diagnosis
B-cell lymphoproliferative disorders
CD13
Waldenström macroglobulinaemia/lymphoplasmatic lymphoma
flow cytometry
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
19
05
2018
accepted:
24
07
2018
pubmed:
11
9
2018
medline:
28
12
2019
entrez:
11
9
2018
Statut:
ppublish
Résumé
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation. It has been suggested that expression of the myeloid marker CD13 (also termed ANPEP) is more frequent in LPL than in other B-LPD and has also been described on normal and malignant plasma cells. Here, CD13 expression was tested in a cohort of 1037 B-LPD patients from 3 centres by flow cytometry. The percentage of CD13-expressing cells was found to be variable among B-LPD but significantly higher in WM/LPL (median 31% vs. 0% in non-WM/LPL, P < 0·001). In multivariate linear regression, CD13 expression remained significantly associated with a diagnosis of WM/LPL (P < 0·001). A cut-off value of 2% of CD19
Substances chimiques
Neoplasm Proteins
0
RNA, Messenger
0
RNA, Neoplasm
0
CD13 Antigens
EC 3.4.11.2
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-633Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.